谷歌浏览器插件
订阅小程序
在清言上使用

Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-Gemox) Versus Rituximab Plus GemOx (R-Gemox) from the Phase III Starglo Study

BLOOD(2024)

引用 0|浏览3
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要